Form D · Biotechnology
ONCOSEC MEDICAL Inc
Ewing, NJ · CIK 0001444307
Offering snapshot reported May 26, 2023 · SEC filing
- Reported sold
- $0 Indefinite offering
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 16, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 26, 2023 | Initial | $0 | No comparison | 7 | SEC filing |
| Apr 24, 2023 | Initial | $0 | No comparison | 7 | SEC filing |
| Nov 28, 2017 | Initial | $5,685,507 | No comparison | 9 | SEC filing |
| Nov 2, 2017 | Initial | $4,941,500 | No comparison | 9 | SEC filing |
| Jul 1, 2011 | Initial | $3,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-482783
In connection with the sale of $1,330,922.88 of common stock, the Issuer issued warrants pursuant to Rule 506(b) for up to 1,408,384 shares of common stock and placement agent warrants exercisable for up to 105,629 shares of common stock ("PA Warrants").
H.C. Wainwright & Co., LLC received $0 for the warrants offered per Rule 506(b). H.C. Wainwright & Co., LLC received sales commission for the sale of common stock in the concurrent registered offering, consisting of cash and PA Warrants.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed May 26, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert H. Arch | Director, Executive |
| George Chi | Executive |
| Michael Cross | Executive |
| James De Mesa | Director |
| Avtar Dhillon | Director |
| Punit Dhillon | Director, Executive |
| Stephany Foster | Director |
| Annalisa Jenkins | Director |
| Joon Kim | Director |
| Herbert Kim Lyerly | Director |
| Anthony Maida | Director |
| Daniel O'connor | Director, Executive |
| Linda Shi | Director |
| Richard Slansky | Executive |
| Kevin R Smith | Director |
| Veronica Vallejo | Executive |
| Chao Zhou | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
820 Bear Tavern Road
Ewing, NJ, 08628
Ewing, NJ, 08628